Advertisement

The European Journal of Health Economics

, Volume 20, Issue 8, pp 1281–1282 | Cite as

Sustainability of public finances: inclusion of unrelated medical cost only part of the story

  • Mark P. ConnollyEmail author
  • Nikolaos Kotsopoulos
  • Aomesh Bhatt
  • Maarten J. Postma
Commentary

We read with interest the paper by van Baal et al. establishing the case for including unrelated healthcare costs in economic evaluations to inform decisions on resource allocation in health [1]. The approach proposed by van Baal and colleagues recognizes the externalities of improving health status and the likelihood of ongoing health costs that can arise in relation to allocating decisions. We broadly agree with the premise proposed by the authors, however, we suggest that if we recognize that treating one medical condition gives rise to future externalities and thus the need for healthcare related transfers, we question why stopping at the inclusion of unrelated healthcare costs to economic evaluations and why not consider a broader analytic perspective that includes a range of public costs and benefits attributed to changes in morbidity or mortality that can be attributable to a new intervention or allocation decision.

The authors highlight that ageing populations will increase...

Notes

Acknowledgements

No funding was received in relation to the work described here. AB served as Member of NICE Technology Appraisal Committee (2012–2018); however, the views and opinions expressed in this article are those of the author and do not necessarily reflect the official policy or position of NICE from his prior engagement.

References

  1. 1.
    van Baal, P., Morton, A., Meltzer, D., Brouwer, W.: Future unrelated medical costs need to be considered in cost effectiveness analysis. Eur. J. Health Econ. 20(1), 1–5 (2019).  https://doi.org/10.1007/s10198-018-0976-0 CrossRefPubMedGoogle Scholar
  2. 2.
    Schofield, D.J., Shrestha, R.N., Percival, R., Passey, M.E., Kelly, S.J., Callander, E.J.: Economic impacts of illness in older workers: quantifying the impact of illness on income, tax revenue and government spending. BMC Public Health 11(1), 418 (2011).  https://doi.org/10.1186/1471-2458-11-418 CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Connolly, M.P., Kotsopoulos, N., Postma, M.J., Bhatt, A.: The Fiscal consequences attributed to changes in morbidity and mortality linked to investments in health care: a government perspective analytic framework. Value Health J. Int. Soc. Pharmacoecon. Outcomes Res. 20(2), 273–277 (2017).  https://doi.org/10.1016/j.jval.2016.11.018 CrossRefGoogle Scholar
  4. 4.
    Goldman, D., Michaud, P.-C., Lakdawalla, D., Zheng, Y., Gailey, A., Vaynman, I.: The fiscal consequences of trends in population health. Natl. Tax J. 63(2), 307–331 (2010)CrossRefGoogle Scholar
  5. 5.
    Black: Working for a healthier tomorrow. In: Pensions, S.o.S.f.H.a.t.S.o.S.f.W.a. (ed.) Working for a healthier tomorrow. London, (2008)Google Scholar
  6. 6.
    Connolly, M.P., Kotsopoulos, N., Ustianowski, A.: Modeling the fiscal costs and benefits of alternative treatment strategies in the United Kingdom for chronic hepatitis C. J. Med. Econ. 21(1), 19–26 (2018).  https://doi.org/10.1080/13696998.2017.1371032 CrossRefPubMedGoogle Scholar
  7. 7.
    Wolf, D.A., Lee, R.D., Miller, T., Donehower, G., Genest, A.: Fiscal externalities of becoming a parent. Popul. Dev. Rev. 37(2), 241–266 (2011).  https://doi.org/10.1111/j.1728-4457.2011.00410.x CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Lee, R.D., Mason, A.: Population Aging and the Generational Economy: A Global Perspective. Edward Elgar Publishing, Cheltenham (2011)CrossRefGoogle Scholar
  9. 9.
    OECD: OECD Health Spending. https://data.oecd.org/healthres/health-spending.htm (2018). Accessed 5 Apr 2019
  10. 10.
    Connolly, M.: The Fiscal impact of investments in health care. Future Health Econ. 2016, 203–213 (2016)Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Global Market Access Solutions SarlSt-PrexSwitzerland
  2. 2.Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of PharmacyUniversity of GroningenGroningenThe Netherlands
  3. 3.Department of EconomicsUniversity of AthensAthensGreece
  4. 4.Reckitt Benckiser Research and DevelopmentSloughUK
  5. 5.Unit of Global Health, Department of Health SciencesUniversity of Groningen, University Medical Center Groningen (UMCG)GroningenThe Netherlands
  6. 6.Department of Economics, Econometrics and FinanceUniversity of Groningen, Faculty of Economics and BusinessGroningenThe Netherlands
  7. 7.Department of Pharmacology and TherapyAirlangga UniversitySurabayaIndonesia

Personalised recommendations